gastro-oesophageal reflux disease
Gastroenterology · 2022–2022
1decision
1medicine
0carried consumer input
0individual submissions
No submission for this condition has carried consumer input, including the one made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| rabeprazole Gastro-oesophageal reflux disease (GORD), prevention of relapse of GORD, symptomatic treatment of GORD, and treatment of active duodenal or gastric ulcer. | Mar 2022 | Recommended | none received |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.